{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T15:48:17Z","timestamp":1769269697572,"version":"3.49.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,8,23]],"date-time":"2018-08-23T00:00:00Z","timestamp":1534982400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lung"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s00408-018-0151-5","type":"journal-article","created":{"date-parts":[[2018,8,23]],"date-time":"2018-08-23T15:54:51Z","timestamp":1535039691000},"page":"517-530","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Comparative Efficacy of Anti IL-4, IL-5 and IL-13 Drugs for Treatment of Eosinophilic Asthma: A Network Meta-analysis"],"prefix":"10.1007","volume":"196","author":[{"given":"Imran H.","family":"Iftikhar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathew","family":"Schimmel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Bender","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colin","family":"Swenson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Amrol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,8,23]]},"reference":[{"key":"151_CR1","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1164\/rccm.201109-1640OC","volume":"185","author":"KW McGrath","year":"2012","unstructured":"McGrath KW, Icitovic N, Boushey HA, Lazarus SC, Sutherland ER, Chinchilli VM, Fahy JV, Asthma Clinical Research Network of the National Heart, Lung, and Blood Institute (2012) A large subgroup of mild-to-moderate asthma is persistently noneosinophilic. Am J Respir Crit Care Med 185:612\u2013619","journal-title":"Am J Respir Crit Care Med"},{"key":"151_CR2","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1164\/rccm.201611-2232PP","volume":"197","author":"TF Carr","year":"2018","unstructured":"Carr TF, Zeki AA, Kraft M (2018) Eosinophilic and noneosinophilic asthma. Am J Respir Crit Care Med 197:22\u201337","journal-title":"Am J Respir Crit Care Med"},{"key":"151_CR3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/ni.3049","volume":"16","author":"BN Lambrecht","year":"2015","unstructured":"Lambrecht BN, Hammad H (2015) The immunology of asthma. Nat Immunol 16:45\u201356","journal-title":"Nat Immunol"},{"key":"151_CR4","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1183\/09031936.00202013","volume":"43","author":"KF Chung","year":"2014","unstructured":"Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, Adcock IM, Bateman ED, Bel EH, Bleecker ER et al (2014) International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 43:343\u2013373","journal-title":"Eur Respir J"},{"key":"151_CR5","doi-asserted-by":"publisher","first-page":"63","DOI":"10.4103\/2229-516X.136774","volume":"4","author":"R Kumar","year":"2014","unstructured":"Kumar R, Singh J (2014) Biosimilar drugs: current status. Int J Appl Basic Med Res 4:63\u201366","journal-title":"Int J Appl Basic Med Res"},{"key":"151_CR6","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1001\/jama.2017.8372","volume":"318","author":"JL McCracken","year":"2017","unstructured":"McCracken JL, Veeranki SP, Ameredes BT, Calhoun WJ (2017) Diagnosis and management of asthma in adults: a review. JAMA 318:279\u2013290","journal-title":"JAMA"},{"key":"151_CR7","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1517\/14712598.2012.642359","volume":"12","author":"A Ghazi","year":"2012","unstructured":"Ghazi A, Trikha A, Calhoun WJ (2012) Benralizumab\u2013a humanized mAb to IL-5Ralpha with enhanced antibody-dependent cell-mediated cytotoxicity\u2013a novel approach for the treatment of asthma. Expert Opin Biol Ther 12:113\u2013118","journal-title":"Expert Opin Biol Ther"},{"key":"151_CR8","doi-asserted-by":"publisher","first-page":"123","DOI":"10.2147\/JAA.S52387","volume":"7","author":"A Vatrella","year":"2014","unstructured":"Vatrella A, Fabozzi I, Calabrese C, Maselli R, Pelaia G (2014) Dupilumab: a novel treatment for asthma. J Asthma Allergy 7:123\u2013130","journal-title":"J Asthma Allergy"},{"key":"151_CR9","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1097\/MCP.0000000000000438","volume":"24","author":"M Humbert","year":"2018","unstructured":"Humbert M, Busse W, Hanania NA (2018) Controversies and opportunities in severe asthma. Curr Opin Pulm Med 24:83\u201393","journal-title":"Curr Opin Pulm Med"},{"key":"151_CR10","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S2213-2600(16)30265-X","volume":"4","author":"NA Hanania","year":"2016","unstructured":"Hanania NA, Korenblat P, Chapman KR, Bateman ED, Kopecky P, Paggiaro P, Yokoyama A, Olsson J, Gray S, Holweg CT et al (2016) Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir Med 4:781\u2013796","journal-title":"Lancet Respir Med"},{"key":"151_CR11","first-page":"1197","volume":"14","author":"IH Iftikhar","year":"2017","unstructured":"Iftikhar IH, Alghothani L, Sardi A, Berkowitz D, Musani AI (2017) Transbronchial lung cryobiopsy and video-assisted thoracoscopic lung biopsy in the diagnosis of diffuse parenchymal lung disease. a meta-analysis of diagnostic test accuracy. Ann Am Thorac Soc 14:1197\u20131211","journal-title":"Ann Am Thorac Soc"},{"key":"151_CR12","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1111\/ene.13449","volume":"24","author":"IH Iftikhar","year":"2017","unstructured":"Iftikhar IH, Alghothani L, Trotti LM (2017) Gabapentin enacarbil, pregabalin and rotigotine are equally effective in restless legs syndrome: a comparative meta-analysis. Eur J Neurol 24:1446\u20131456","journal-title":"Eur J Neurol"},{"key":"151_CR13","unstructured":"Higgins JPT, Green S (eds) (2011) Cochrane handbook for systematic reviews of interventions version 5.1.0 (updated March 2011). The Cochrane Collaboration. Available from \n                    http:\/\/www.cochrane-handbook.org"},{"key":"151_CR14","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1002\/jrsm.1058","volume":"3","author":"G Rucker","year":"2012","unstructured":"Rucker G (2012) Network meta-analysis, electrical networks and graph theory. Res Synth Methods 3:312\u2013324","journal-title":"Res Synth Methods"},{"key":"151_CR15","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","volume":"388","author":"ER Bleecker","year":"2016","unstructured":"Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P, Sproule S, Gilmartin G, Aurivillius M, Werkstrom V et al (2016) Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet 388:2115\u20132127","journal-title":"Lancet"},{"key":"151_CR16","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/S2213-2600(17)30190-X","volume":"5","author":"GT Ferguson","year":"2017","unstructured":"Ferguson GT, FitzGerald JM, Bleecker ER, Laviolette M, Bernstein D, LaForce C, Mansfield L, Barker P, Wu Y, Jison M et al (2017) Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med 5:568\u2013576","journal-title":"Lancet Respir Med"},{"key":"151_CR17","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","volume":"388","author":"JM FitzGerald","year":"2016","unstructured":"FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, Ferguson GT, Busse WW, Barker P, Sproule S et al (2016) Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 388:2128\u20132141","journal-title":"Lancet"},{"key":"151_CR18","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.chest.2016.03.018","volume":"150","author":"J Corren","year":"2016","unstructured":"Corren J, Weinstein S, Janka L, Zangrilli J, Garin M (2016) Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts. Chest 150:799\u2013810","journal-title":"Chest"},{"key":"151_CR19","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1056\/NEJMoa1106469","volume":"365","author":"J Corren","year":"2011","unstructured":"Corren J, Lemanske RF, Hanania NA, Korenblat PE, Parsey MV, Arron JR, Harris JM, Scheerens H, Wu LC, Su Z et al (2011) Lebrikizumab treatment in adults with asthma. N Engl J Med 365:1088\u20131098","journal-title":"N Engl J Med"},{"key":"151_CR20","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/S2213-2600(14)70201-2","volume":"2","author":"M Castro","year":"2014","unstructured":"Castro M, Wenzel SE, Bleecker ER, Pizzichini E, Kuna P, Busse WW, Gossage DL, Ward CK, Wu Y, Wang B et al (2014) Benralizumab, an anti-interleukin 5 receptor alpha monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir Med 2:879\u2013890","journal-title":"Lancet Respir Med"},{"key":"151_CR21","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP et al (2015) The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 162:777\u2013784","journal-title":"Ann Intern Med"},{"key":"151_CR22","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","volume":"376","author":"P Nair","year":"2017","unstructured":"Nair P, Wenzel S, Rabe KF, Bourdin A, Lugogo NL, Kuna P, Barker P, Sproule S, Ponnarambil S, Goldman M et al (2017) Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med 376:2448\u20132458","journal-title":"N Engl J Med"},{"key":"151_CR23","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ajem.2014.09.036","volume":"33","author":"RM Nowak","year":"2015","unstructured":"Nowak RM, Parker JM, Silverman RA, Rowe BH, Smithline H, Khan F, Fiening JP, Kim K, Molfino NA (2015) A randomized trial of benralizumab, an antiinterleukin 5 receptor alpha monoclonal antibody, after acute asthma. Am J Emerg Med 33:14\u201320","journal-title":"Am J Emerg Med"},{"key":"151_CR24","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1159\/000444799","volume":"169","author":"HS Park","year":"2016","unstructured":"Park HS, Kim MK, Imai N, Nakanishi T, Adachi M, Ohta K, Tohda Y (2016) Asian benralizumab study G: a phase 2a study of benralizumab for patients with eosinophilic asthma in South Korea and Japan. Int Arch Allergy Immunol 169:135\u2013145","journal-title":"Int Arch Allergy Immunol"},{"key":"151_CR25","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(16)30307-5","volume":"388","author":"S Wenzel","year":"2016","unstructured":"Wenzel S, Castro M, Corren J, Maspero J, Wang L, Zhang B, Pirozzi G, Sutherland ER, Evans RR, Joish VN et al (2016) Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting beta2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet 388:31\u201344","journal-title":"Lancet"},{"key":"151_CR26","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1304048","volume":"368","author":"S Wenzel","year":"2013","unstructured":"Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobieranda F, Wang L, Kirkesseli S, Rocklin R, Bock B et al (2013) Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 368:2455\u20132466","journal-title":"N Engl J Med"},{"key":"151_CR27","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1136\/thoraxjnl-2014-206719","volume":"70","author":"NA Hanania","year":"2015","unstructured":"Hanania NA, Noonan M, Corren J, Korenblat P, Zheng Y, Fischer SK, Cheu M, Putnam WS, Murray E, Scheerens H et al (2015) Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies. Thorax 70:748\u2013756","journal-title":"Thorax"},{"key":"151_CR28","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.jaci.2013.03.051","volume":"132","author":"M Noonan","year":"2013","unstructured":"Noonan M, Korenblat P, Mosesova S, Scheerens H, Arron JR, Zheng Y, Putnam WS, Parsey MV, Bohen SP, Matthews JG (2013) Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids. J Allergy Clin Immunol 132:567\u2013574 e512","journal-title":"J Allergy Clin Immunol"},{"key":"151_CR29","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","volume":"371","author":"EH Bel","year":"2014","unstructured":"Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, Ortega HG, Pavord ID, Investigators S (2014) Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 371:1189\u20131197","journal-title":"N Engl J Med"},{"key":"151_CR30","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/S2213-2600(17)30125-X","volume":"5","author":"GL Chupp","year":"2017","unstructured":"Chupp GL, Bradford ES, Albers FC, Bratton DJ, Wang-Jairaj J, Nelsen LM, Trevor JL, Magnan A, Ten Brinke A (2017) Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med 5:390\u2013400","journal-title":"Lancet Respir Med"},{"key":"151_CR31","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1164\/rccm.200701-085OC","volume":"176","author":"P Flood-Page","year":"2007","unstructured":"Flood-Page P, Swenson C, Faiferman I, Matthews J, Williams M, Brannick L, Robinson D, Wenzel S, Busse W, Hansel TT et al (2007) A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med 176:1062\u20131071","journal-title":"Am J Respir Crit Care Med"},{"key":"151_CR32","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1056\/NEJMoa0808991","volume":"360","author":"P Haldar","year":"2009","unstructured":"Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, Marshall RP, Bradding P, Green RH, Wardlaw AJ et al (2009) Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 360:973\u2013984","journal-title":"N Engl J Med"},{"key":"151_CR33","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1056\/NEJMoa0805435","volume":"360","author":"P Nair","year":"2009","unstructured":"Nair P, Pizzichini MM, Kjarsgaard M, Inman MD, Efthimiadis A, Pizzichini E, Hargreave FE, O\u2019Byrne PM (2009) Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 360:985\u2013993","journal-title":"N Engl J Med"},{"key":"151_CR34","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","volume":"371","author":"HG Ortega","year":"2014","unstructured":"Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, Humbert M, Katz LE, Keene ON, Yancey SW et al (2014) Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 371:1198\u20131207","journal-title":"N Engl J Med"},{"key":"151_CR35","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","volume":"380","author":"ID Pavord","year":"2012","unstructured":"Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, Ortega H, Chanez P (2012) Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 380:651\u2013659","journal-title":"Lancet"},{"key":"151_CR36","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.chest.2016.03.032","volume":"150","author":"L Bjermer","year":"2016","unstructured":"Bjermer L, Lemiere C, Maspero J, Weiss S, Zangrilli J, Germinaro M (2016) Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study. Chest 150:789\u2013798","journal-title":"Chest"},{"key":"151_CR37","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1164\/rccm.201103-0396OC","volume":"184","author":"M Castro","year":"2011","unstructured":"Castro M, Mathur S, Hargreave F, Boulet LP, Xie F, Young J, Wilkins HJ, Henkel T, Nair P (2011) Res-5\u2014study G: reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med 184:1125\u20131132","journal-title":"Am J Respir Crit Care Med"},{"key":"151_CR38","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","volume":"3","author":"M Castro","year":"2015","unstructured":"Castro M, Zangrilli J, Wechsler ME, Bateman ED, Brusselle GG, Bardin P, Murphy K, Maspero JF, O\u2019Brien C, Korn S (2015) Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med 3:355\u2013366","journal-title":"Lancet Respir Med"},{"key":"151_CR39","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/S2213-2600(15)00197-6","volume":"3","author":"CE Brightling","year":"2015","unstructured":"Brightling CE, Chanez P, Leigh R, O\u2019Byrne PM, Korn S, She D, May RD, Streicher K, Ranade K, Piper E (2015) Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respir Med 3:692\u2013701","journal-title":"Lancet Respir Med"},{"key":"151_CR40","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1183\/09031936.00223411","volume":"41","author":"E Piper","year":"2013","unstructured":"Piper E, Brightling C, Niven R, Oh C, Faggioni R, Poon K, She D, Kell C, May RD, Geba GP et al (2013) A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma. Eur Respir J 41:330\u2013338","journal-title":"Eur Respir J"},{"key":"151_CR41","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.jaci.2013.03.044","volume":"132","author":"AT Hastie","year":"2013","unstructured":"Hastie AT, Moore WC, Li H, Rector BM, Ortega VE, Pascual RM, Peters SP, Meyers DA, Bleecker ER, National Heart L et al (2013) Biomarker surrogates do not accurately predict sputum eosinophil and neutrophil percentages in asthmatic subjects. J Allergy Clin Immunol 132:72\u201380","journal-title":"J Allergy Clin Immunol"},{"key":"151_CR42","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1136\/thoraxjnl-2014-205634","volume":"70","author":"AH Wagener","year":"2015","unstructured":"Wagener AH, de Nijs SB, Lutter R, Sousa AR, Weersink EJ, Bel EH, Sterk PJ (2015) External validation of blood eosinophils, FE(NO) and serum periostin as surrogates for sputum eosinophils in asthma. Thorax 70:115\u2013120","journal-title":"Thorax"},{"key":"151_CR43","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1111\/cea.12345","volume":"44","author":"XY Zhang","year":"2014","unstructured":"Zhang XY, Simpson JL, Powell H, Yang IA, Upham JW, Reynolds PN, Hodge S, James AL, Jenkins C, Peters MJ et al (2014) Full blood count parameters for the detection of asthma inflammatory phenotypes. Clin Exp Allergy 44:1137\u20131145","journal-title":"Clin Exp Allergy"},{"key":"151_CR44","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1097\/00043426-198722000-00005","volume":"9","author":"RD Christensen","year":"1987","unstructured":"Christensen RD, Hill HR (1987) Exercise-induced changes in the blood concentration of leukocyte populations in teenage athletes. Am J Pediatr Hematol Oncol 9:140\u2013142","journal-title":"Am J Pediatr Hematol Oncol"},{"key":"151_CR45","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/j.1398-9995.1977.tb02571.x","volume":"32","author":"R Dahl","year":"1977","unstructured":"Dahl R (1977) Diurnal variation in the number of circulating eosinophil leucocytes in normal controls and asthmatics. Acta Allergol 32:301\u2013303","journal-title":"Acta Allergol"},{"key":"151_CR46","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1164\/rccm.200208-789OC","volume":"167","author":"PT Flood-Page","year":"2003","unstructured":"Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS (2003) Eosinophil\u2019s role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med 167:199\u2013204","journal-title":"Am J Respir Crit Care Med"},{"key":"151_CR47","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1016\/S0140-6736(00)03496-6","volume":"356","author":"MJ Leckie","year":"2000","unstructured":"Leckie MJ, ten Brinke A, Khan J, Diamant Z, O\u2019Connor BJ, Walls CM, Mathur AK, Cowley HC, Chung KF, Djukanovic R et al (2000) Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 356:2144\u20132148","journal-title":"Lancet"},{"key":"151_CR48","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.drudis.2016.11.008","volume":"22","author":"AR Koczulla","year":"2017","unstructured":"Koczulla AR, Vogelmeier CF, Garn H, Renz H (2017) New concepts in asthma: clinical phenotypes and pathophysiological mechanisms. Drug Discov Today 22:388\u2013396","journal-title":"Drug Discov Today"},{"key":"151_CR49","doi-asserted-by":"publisher","first-page":"301ra129","DOI":"10.1126\/scitranslmed.aab3142","volume":"7","author":"DF Choy","year":"2015","unstructured":"Choy DF, Hart KM, Borthwick LA, Shikotra A, Nagarkar DR, Siddiqui S, Jia G, Ohri CM, Doran E, Vannella KM et al (2015) TH2 and TH17 inflammatory pathways are reciprocally regulated in asthma. Sci Transl Med 7:301ra129","journal-title":"Sci Transl Med"}],"container-title":["Lung"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00408-018-0151-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00408-018-0151-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00408-018-0151-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,22]],"date-time":"2019-08-22T23:03:29Z","timestamp":1566515009000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00408-018-0151-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,23]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["151"],"URL":"https:\/\/doi.org\/10.1007\/s00408-018-0151-5","relation":{},"ISSN":["0341-2040","1432-1750"],"issn-type":[{"value":"0341-2040","type":"print"},{"value":"1432-1750","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,23]]},"assertion":[{"value":"12 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}